Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 10/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.53 |
| ▸ | F2RL3 | Q96RI0 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708177 | 0.85 | F2RL3 (0.45) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL16345218 | 0.83 | LMNA (0.43) | LMNARECQLF2RL3ALDH1A1KMT2A | |
| SCHEMBL7422796 | 0.83 | F2RL3 (0.44) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL7049405 | 0.81 | PDE4A (0.59) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL4514609 | 0.81 | ALDH1A1 (0.53) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL7056726 | 0.80 | PDE4A (0.62) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL14981193 | 0.80 | LMNA (0.56) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL8342247 | 0.79 | LMNA (0.55) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL16208258 | 0.79 | LMNA (0.55) | LMNARECQLPDE4APDE4BPDE4C | |
| SCHEMBL7050573 | 0.79 | PDE4A (0.61) | LMNARECQLPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015087094-A1 | NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-06-18 | — | — | WO | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2009-09-03 | — | — | US | disclosed |
| US-7495017-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-24 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| WO-2007123953-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | HOPPER ALLEN | 2007-08-30 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2004-11-18 | — | — | US | disclosed |
| WO-2004094411-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-0901482-B1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-05-02 | — | — | EP | disclosed |
| US-5972936-A | Benzofuran carboxamides and their therapeutic use | DARWIN DISCOVER LIMITED (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5925636-A | Benzofuran carboxamides and their therapeutic use | DARWIN DISCOVERY LIMITED (GB) | 1999-07-20 | — | — | US | disclosed |
| EP-0901482-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | Darwin Discovery Limited (GB) | 1999-03-17 | — | — | EP | disclosed |
| EP-0873331-A1 | BENZOFURAN CARBOXAMIDES AND SULPHONAMIDES | Darwin Discovery Limited (GB) | 1998-10-28 | — | — | EP | disclosed |
| US-5773467-A | Benzofuran sulphonanmides | CHIROSCIENCE, LTD. (GB) | 1998-06-30 | — | — | US | disclosed |
| WO-1997044337-A1 | BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | disclosed |
| WO-1997020833-A1 | BENZOFURAN CARBOXAMIDES AND SULPHONAMIDES | DARWIN DISCOVERY LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | LMNA 3738/4885RECQL 1347/4885PDE4A 1/4885 |
| US-20070203197-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | LMNA 3738/4885RECQL 1347/4885PDE4A 1/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | LMNA 3738/4885RECQL 1347/4885PDE4A 1/4885 |
| US-20090221661-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | LMNA 3738/4885RECQL 1347/4885PDE4A 1/4885 |
| US-20040229918-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | LMNA 3738/4885RECQL 1347/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.